The bound-to-happen changes disclosed Wednesday by Amgen Inc. failed to shock Wall Street, and eyes now have turned to the firm's date with an FDA panel on erythropoietin stimulating agents (ESAs) and a court fight over patents with F. Hoffmann-La Roche Ltd. - even as hopes remain in some quarters that the feds might modify their reimbursement guidelines for anemia drugs. (BioWorld Today)